SCHEMBL465467

SCHEMBL465467

O=Cc1ccc(CCCCCCOc2ccc(C=O)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.65
HPGD P15428 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
LMNA P02545 2/20 0.65
MAPT P10636 2/20 0.65
FFAR1 O14842 2/20 0.51
S1PR1 P21453 6/20 0.50
S1PR3 Q99500 3/20 0.50
S1PR5 Q9H228 1/20 0.50
RAB9A P51151 1/20 0.47
PLA2G4B P0C869 1/20 0.46
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAPK1 P28482 1/20 0.45
CASP1 P29466 1/20 0.45
KMT2A Q03164 1/20 0.45
SLCO1B3 Q9NPD5 1/20 0.45
SLCO1B1 Q9Y6L6 1/20 0.45
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL465533 1.00 ALDH1A1 (0.65) ALDH1A1HPGDSMN1; SMN2LMNAMAPT
SCHEMBL465524 0.98 HPGD (0.67) ALDH1A1HPGDSMN1; SMN2LMNAMAPT
SCHEMBL465539 0.93 HPGD (0.69) ALDH1A1HPGDSMN1; SMN2LMNAMAPT
SCHEMBL3843475 0.92 FFAR1 (0.59) ALDH1A1HPGDSMN1; SMN2LMNAMAPT
SCHEMBL9098252 0.92 FFAR1 (0.59) ALDH1A1HPGDSMN1; SMN2LMNAMAPT
SCHEMBL23627223 0.90 HPGD (0.58) ALDH1A1HPGDSMN1; SMN2LMNAMAPT
SCHEMBL7630422 0.90 ALDH1A1 (0.58) ALDH1A1HPGDSMN1; SMN2LMNAMAPT
SCHEMBL3083583 0.90 FFAR1 (0.60) ALDH1A1HPGDSMN1; SMN2LMNAMAPT
SCHEMBL8374769 0.89 ALDH1A1 (0.67) ALDH1A1HPGDSMN1; SMN2LMNAMAPT
SCHEMBL8549614 0.89 ALDH1A1 (0.67) ALDH1A1HPGDSMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194981-B1 BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS UNIV MONS HAINAUT (BE) 2011-11-23 EP disclosed
US-20100160402-A1 Bisbenzimidazoles as antimalarial agents XAVIER UNIVERSITY OF LOUISIANA 2010-06-24 US disclosed
EP-2194981-A1 BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS Université de Mons-Hainaut (BE) 2010-06-16 EP disclosed
WO-2009043902-A1 BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS UNIVERSITE DE MONS HAINAUT (BE) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160402-A1 Bisbenzimidazoles as antimalarial agents NQO2, SQOR, CPS1 ALDH1A1 2545/4885HPGD 2305/4885SMN1; SMN2 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.